2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - 291-292
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Gene Editing, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Gene Therapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

593 Lentiviral modeling of codanin-1 deficiency reveals a dose-dependent erythroid maturation block and establishes proof of concept for gene therapy of congenital dyserythropoietic anemia type I

Lucas Tricoli, PhD, Kazuhiro Noguchi, MD.,PhD.2, Carlo Castruccio Castracani, PharmD, PhD3, Madison Herling, PhD4, Laura Breda, PhD5, Perry Demsko, PhD6, Tyler Papp7, Ying K Tam8, Barbara Mui, PhD9, Hamideh Parhiz, PhD10, Stefano Rivella, PhD11
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
5 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
6 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
7 University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
8 Acuitas, Vancouver, British Columbia, Canada
9 Acuitas, Vancouver, British Columbia, Canada
10 University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
11 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Abstract:

Background: Congenital dyserythropoietic anemia type I (CDA I) is a rare autosomal recessive disorder characterized by macrocytic anemia and pathognomonic chromatin bridges in bone marrow erythroblasts. CDA I is most commonly caused by biallelic mutations in Codanin-1 (CDAN1), which negatively regulates histone deposition and chromatin accessibility during S phase. Because CDAN1 is essential for basic cell-cycle progression, complete loss of function is poorly tolerated, hampering the generation of durable models needed to link CDAN1 dysfunction specifically to impaired erythroid differentiation. We therefore developed an inducible Cdan1-knockout mouse model and a lentiviral vector to titrate Cdan1/CDAN1 knockdown, rather than complete ablation, to more faithfully model the human disease. In addition, we generated a gene therapy vector to assess its ability to rescue CDA I.

Methods: We generated a conditional, inducible Cdan1-knockout mouse (Cdan1-fl/fl; Mx1-Cre) and observed that poly(I:C)-induced, whole-body Cdan1 deletion is rapidly lethal (~20-25 days) with severe anemia, reduced hematocrit, and reticulocyte/white cell abnormalities, establishing that complete Cdan1 loss is not a viable chronic model. We designed an LV expressing an shRNA targeting mouse or human CDAN1 (versus a scrambled control), validated knockdown by western blot in K562 cells and cytosolic/nuclear fractions, and confirmed reduced proliferation of knocked-down K562 cells. We transplanted lethally irradiated mice with lineage-negative bone marrow transduced with shRNA or scramble LV, and tracked engraftment (GFP, vector copy number [VCN]), blood counts, survival, and marrow lineage composition by flow cytometry, including GFP-intensity sorting as a surrogate for knockdown level. In parallel, human CD34+ cells were transduced with shRNA or scramble LV and assessed for CDAN1 knockdown, proliferation, viability, hemoglobinization, cell-cycle kinetics, and chromatin bridging during erythroid differentiation. Finally, we tested rescue of the Cdan1-knockout phenotype by engrafting bone marrow cells in which the Cdan1-fl/fl gene was deleted using Cre mRNA delivered via lipid nanoparticles and transduced with an LV expressing human CDAN1 (AP-CDAN1-FWP).

Results: Mice transplanted with Cdan1-shRNA-LV-transduced marrow developed dose-dependent anemia tracking with GFP expression level: mice with the highest shRNA expression (GFP-high) had the lowest RBC, hemoglobin, and hematocrit and reduced survival versus scramble controls and GFP-low counterparts, while VCN declined progressively in shRNA-transduced cells over time, indicating negative selection against strongly knocked-down clones. Bone marrow flow cytometry showed selective loss of GFP+ Ter119+ erythroid cells with skewing toward immature erythroid stages (R1-R2). Additionally, we observed a similar trend across the granulocyte, B-cell, and CD3+ T-cell compartments, indicating an erythroid-lineage-specific maturation block, with potentially more limited effects on other lineages. Human CD34+ cells transduced with CDAN1-shRNA showed reduced CDAN1 protein levels by western blot, impaired proliferation and viability, and visibly reduced hemoglobinization during erythroid differentiation compared with scramble controls. Cytospins of differentiating shRNA-treated human cells showed increased chromatin bridging and altered cell-cycle/maturation marker (CD71, Band3) distribution, recapitulating the histologic hallmark of CDA I. Lentiviral expression of human CDAN1 in Cdan1-knockout mice rescued survival and normalized RBC, hemoglobin, and hematocrit versus non-rescued knockout controls, with preserved marrow histology in rescued animals.

Conclusion: While complete Cdan1 loss is incompatible with long-term survival in adult mice, partial, titratable knockdown using an shRNA LV generates a viable, dose-dependent model recapitulating the core features of CDA I, including anemia, an erythroid-specific maturation block, and chromatin bridging, in both mouse and human hematopoietic cells. Rescue by lentiviral CDAN1 addition confirms phenotype specificity and provides proof of concept for CDAN1 gene replacement as therapy. This tunable model establishes a platform to characterize the role of CDAN1-dependent chromatin regulation in hematopoietic stem and erythroid cells, and to test gene and cell therapy approaches for CDA I.

Stefano Rivella, PhD: Disc Medicine - Current holder of stock options in a privately-held company; Ferrosa Therapeutics - Honoraria; Disc Medicine - Honoraria; Disc Medicine - Research Funding; Ferrosa Therapeutics - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony)